Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $2,246,952.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) major shareholder Vivek Ramaswamy sold 200,800 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $11.19, for a total value of $2,246,952.00. Following the completion of the transaction, the insider now owns 38,426,381 shares in the company, valued at $429,991,203.39. This represents a 0.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Vivek Ramaswamy also recently made the following trade(s):

• On Wednesday, June 4th, Vivek Ramaswamy sold 547,430 shares of Roivant Sciences stock. The stock was sold at an average price of $11.34, for a total value of $6,207,856.20.
• On Tuesday, May 6th, Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73.

Roivant Sciences Trading Up 0.3%

ROIV opened at $11.23 on Monday. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06. The stock has a market capitalization of $8.01 billion, a price-to-earnings ratio of -74.86 and a beta of 1.16. The business has a 50 day moving average of $10.64 and a 200-day moving average of $11.01.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The business had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. During the same period in the prior year, the company posted ($0.23) earnings per share. Equities analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on ROIV. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, May 28th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ROIV. Norges Bank bought a new position in Roivant Sciences in the fourth quarter worth $52,443,000. Nuveen LLC bought a new position in Roivant Sciences in the first quarter worth $31,988,000. Invesco Ltd. raised its stake in Roivant Sciences by 49.7% during the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company’s stock worth $112,563,000 after acquiring an additional 3,159,603 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Roivant Sciences by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after acquiring an additional 2,404,232 shares during the period. Finally, TOMS Capital Investment Management LP lifted its holdings in shares of Roivant Sciences by 46.6% during the fourth quarter. TOMS Capital Investment Management LP now owns 5,885,000 shares of the company’s stock valued at $69,620,000 after acquiring an additional 1,870,000 shares during the period. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.